Q32 Bio names José Trevejo CMO and Ellie Hershberger CDO; bempikibart registration program targeted H1 2027

Q32 Bio Inc.

José Trevejo, M.D., Ph.D. named CMO; ex-CMO at Tarsus (helped win FDA approval of XDEMVY for Demodex blepharitis) and ex-CDO at Rocket Pharmaceuticals.
Ellie Hershberger, Pharm.D. named CDO; ex-CDO at Adagio/Invivyd, led antibody from IND-enabling to Phase 3 and helped raise ~$356M in IPO gross proceeds.
Company targets advancing bempikibart into registration-directed program for severe or very severe alopecia areata in first half of 2027.
Q32 Bio says SIGNAL-AA Part B showed meaningful hair regrowth, early durability off-drug, and generally well-tolerated safety profile for bempikibart.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.